Matches in SemOpenAlex for { <https://semopenalex.org/work/W2073035081> ?p ?o ?g. }
- W2073035081 endingPage "1410" @default.
- W2073035081 startingPage "1400" @default.
- W2073035081 abstract "Thiazolidinediones (TZDs) are widely used oral antihyperglycemic drugs that facilitate insulin action and increase insulin-stimulated glucose metabolism, thereby decreasing insulin resistance. However, concerns have been raised regarding the association between TZD use and a heightened risk for congestive heart failure (CHF).This study used claims data to conduct a retrospective examination of the CHF risk in patients with type 2 diabetes mellitus and to compare the association with CHF in those receiving the TZD pioglitazone and those receiving insulin.Patients with type 2 diabetes aged > or =18 years who had begun treatment with pioglitazone or insulin between January 1999 and December 2001 were identified using the PharMetrics Patient-Centric database. The sample was restricted to patients for whom there were > or =12 months of data before the index date (date of the first prescription for pioglitazone or insulin) and > or =3 months of follow-up data. Patients receiving a diagnosis of CHF before the index date were excluded. The propensity score for receiving pioglitazone was estimated using logistic regression based on available observed patient characteristics. Patients receiving insulin were matched in a 1:1 ratio with patients receiving pioglitazone based on a difference of no more than +/-0.01 in the estimated propensity score for receiving pioglitazone therapy. CHF risk was examined using the Cox proportional-hazards model.After exclusion of ineligible patients, 1668 matched pairs of patients receiving pioglitazone or insulin were identified (50.9% men, 49.1% women; mean [SE] age, 51.2 [0.2] years). The 2-year crude incidence rate of CHF was significantly lower in the pioglitazone group compared with the insulin group (primary/secondary diagnosis of CHF, 2.0% vs 4.0%, respectively; P < 0.001; inpatient hospitalization for CHF, 0.7% vs 2.5%; P < 0.001). The hazard ratio for pioglitazone versus insulin was 0.501 (95% CI, 0.331-0.758; P = 0.001) for a primary or secondary diagnosis of CHF in any setting and 0.263 (95% CI, 0.135-0.511; P < 0.001) for any occurrence of an inpatient hospitalization for CHF.In this retrospective analysis of data from patients with type 2 diabetes, pioglitazone therapy was associated with significantly lower incidence rates of CHF and inpatient hospitalization compared with insulin therapy." @default.
- W2073035081 created "2016-06-24" @default.
- W2073035081 creator A5010066358 @default.
- W2073035081 creator A5038671951 @default.
- W2073035081 creator A5050491207 @default.
- W2073035081 creator A5060465607 @default.
- W2073035081 creator A5087149160 @default.
- W2073035081 date "2004-09-01" @default.
- W2073035081 modified "2023-09-27" @default.
- W2073035081 title "Association between congestive heart failure and hospitalization in patients with type 2 diabetes mellitus receiving treatment with insulin or pioglitazone: a retrospective data analysis" @default.
- W2073035081 cites W1580788756 @default.
- W2073035081 cites W1910926186 @default.
- W2073035081 cites W1964716328 @default.
- W2073035081 cites W1984030224 @default.
- W2073035081 cites W1989619519 @default.
- W2073035081 cites W2000445173 @default.
- W2073035081 cites W2015279471 @default.
- W2073035081 cites W2019007750 @default.
- W2073035081 cites W2023447984 @default.
- W2073035081 cites W2028038659 @default.
- W2073035081 cites W2030973204 @default.
- W2073035081 cites W2051159435 @default.
- W2073035081 cites W2051727048 @default.
- W2073035081 cites W2052806549 @default.
- W2073035081 cites W2056726092 @default.
- W2073035081 cites W2069150029 @default.
- W2073035081 cites W2078807483 @default.
- W2073035081 cites W2092881968 @default.
- W2073035081 cites W2094394439 @default.
- W2073035081 cites W2094910754 @default.
- W2073035081 cites W2100500261 @default.
- W2073035081 cites W2113174062 @default.
- W2073035081 cites W2121690051 @default.
- W2073035081 cites W2124411103 @default.
- W2073035081 cites W2125916336 @default.
- W2073035081 cites W2128712342 @default.
- W2073035081 cites W2129168200 @default.
- W2073035081 cites W2131669718 @default.
- W2073035081 cites W2135378280 @default.
- W2073035081 cites W2160047435 @default.
- W2073035081 cites W2164367541 @default.
- W2073035081 cites W2169005776 @default.
- W2073035081 cites W22189248 @default.
- W2073035081 cites W2275139239 @default.
- W2073035081 cites W2288490027 @default.
- W2073035081 cites W2331274940 @default.
- W2073035081 cites W2337454357 @default.
- W2073035081 cites W2462655570 @default.
- W2073035081 cites W2612654823 @default.
- W2073035081 cites W2802955619 @default.
- W2073035081 cites W2995133996 @default.
- W2073035081 doi "https://doi.org/10.1016/j.clinthera.2004.09.016" @default.
- W2073035081 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/15531002" @default.
- W2073035081 hasPublicationYear "2004" @default.
- W2073035081 type Work @default.
- W2073035081 sameAs 2073035081 @default.
- W2073035081 citedByCount "47" @default.
- W2073035081 countsByYear W20730350812013 @default.
- W2073035081 countsByYear W20730350812014 @default.
- W2073035081 countsByYear W20730350812015 @default.
- W2073035081 countsByYear W20730350812022 @default.
- W2073035081 countsByYear W20730350812023 @default.
- W2073035081 crossrefType "journal-article" @default.
- W2073035081 hasAuthorship W2073035081A5010066358 @default.
- W2073035081 hasAuthorship W2073035081A5038671951 @default.
- W2073035081 hasAuthorship W2073035081A5050491207 @default.
- W2073035081 hasAuthorship W2073035081A5060465607 @default.
- W2073035081 hasAuthorship W2073035081A5087149160 @default.
- W2073035081 hasConcept C126322002 @default.
- W2073035081 hasConcept C134018914 @default.
- W2073035081 hasConcept C167135981 @default.
- W2073035081 hasConcept C17923572 @default.
- W2073035081 hasConcept C2777180221 @default.
- W2073035081 hasConcept C2778198053 @default.
- W2073035081 hasConcept C2778384471 @default.
- W2073035081 hasConcept C2779306644 @default.
- W2073035081 hasConcept C2910068830 @default.
- W2073035081 hasConcept C555293320 @default.
- W2073035081 hasConcept C71924100 @default.
- W2073035081 hasConceptScore W2073035081C126322002 @default.
- W2073035081 hasConceptScore W2073035081C134018914 @default.
- W2073035081 hasConceptScore W2073035081C167135981 @default.
- W2073035081 hasConceptScore W2073035081C17923572 @default.
- W2073035081 hasConceptScore W2073035081C2777180221 @default.
- W2073035081 hasConceptScore W2073035081C2778198053 @default.
- W2073035081 hasConceptScore W2073035081C2778384471 @default.
- W2073035081 hasConceptScore W2073035081C2779306644 @default.
- W2073035081 hasConceptScore W2073035081C2910068830 @default.
- W2073035081 hasConceptScore W2073035081C555293320 @default.
- W2073035081 hasConceptScore W2073035081C71924100 @default.
- W2073035081 hasIssue "9" @default.
- W2073035081 hasLocation W20730350811 @default.
- W2073035081 hasLocation W20730350812 @default.
- W2073035081 hasOpenAccess W2073035081 @default.
- W2073035081 hasPrimaryLocation W20730350811 @default.
- W2073035081 hasRelatedWork W1983641721 @default.
- W2073035081 hasRelatedWork W1994230976 @default.
- W2073035081 hasRelatedWork W2026226896 @default.